$NBIO News: Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company", a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the completion of dosing of the second cohort of patients involved in the Company's Phase I trial to evaluate Pritumumab ("PTB" as a treatment for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases.

"After reviewing data gathered from the first and second cohorts, this milestone will allow us to quickly advance to our third cohort in the study, which is anticipated to start this month," noted Nascent CEO, Sean Carrick.

PTB is a natural human antibody that works by binding to Cell surface Vimentin (also referred to as ectodomain vimentin, or EDV), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy that, unlike chemotherapy, only targets cancer cells without damaging healthy cells.